giancarlo antonucci - eventi5 · icsh laboratory measurements of doac recommendations trough drug...
TRANSCRIPT
![Page 1: Giancarlo Antonucci - Eventi5 · ICSH Laboratory Measurements of DOAC recommendations Trough drug level assessment for non emergent situations, with results reported in ng/mL International](https://reader031.vdocument.in/reader031/viewer/2022011918/6001c06be6acb16e56788dd8/html5/thumbnails/1.jpg)
Giancarlo Antonucci
EO Galliera SC medicina /SSD Area critica Genova
II Sessione EMOSTASI E TROMBOSI Terapia antitrombotica nella fibrillazione atriale
![Page 2: Giancarlo Antonucci - Eventi5 · ICSH Laboratory Measurements of DOAC recommendations Trough drug level assessment for non emergent situations, with results reported in ng/mL International](https://reader031.vdocument.in/reader031/viewer/2022011918/6001c06be6acb16e56788dd8/html5/thumbnails/2.jpg)
>65 yrs 9%
2018: 67%-88% of A F patients are on anticoagulation
Bungard TJ et al. Arch Intern Med. 2000;160:41–46.
Why do patients with atrial fibrillation not receive warfarin?
• unpredictable response • slow onset and offset of the
pharmacological effect • narrow therapeutic window • numerous interactions with
other drugs and foods
![Page 3: Giancarlo Antonucci - Eventi5 · ICSH Laboratory Measurements of DOAC recommendations Trough drug level assessment for non emergent situations, with results reported in ng/mL International](https://reader031.vdocument.in/reader031/viewer/2022011918/6001c06be6acb16e56788dd8/html5/thumbnails/3.jpg)
Dabigatran Rivaroxaban
2008 Apixaban 2011 Edoxabann 2015
prevention of stroke and systemic embolism
in patients with NVAF
![Page 4: Giancarlo Antonucci - Eventi5 · ICSH Laboratory Measurements of DOAC recommendations Trough drug level assessment for non emergent situations, with results reported in ng/mL International](https://reader031.vdocument.in/reader031/viewer/2022011918/6001c06be6acb16e56788dd8/html5/thumbnails/4.jpg)
Different mechanisms of action
Y. Ingrasciotta et al.(2018) Pharmacokinetics of new oral anticoagulants: implications for use in routine care, Expert Opinion on Drug Metabolism & Toxicology, 14:10, 1057
![Page 5: Giancarlo Antonucci - Eventi5 · ICSH Laboratory Measurements of DOAC recommendations Trough drug level assessment for non emergent situations, with results reported in ng/mL International](https://reader031.vdocument.in/reader031/viewer/2022011918/6001c06be6acb16e56788dd8/html5/thumbnails/5.jpg)
Reproduced from Ruff et al.36 with permission. Ruff et al. Lancet 2014;383:955-62
(A)Stroke or systemic embolic events - (B) Major bleeding. Data are n/N, unless otherwise indicated. Heterogeneity: I2 = 47%; P = 0·13. NOAC, new oral anticoagulant; RR, risk ratio. *, dabigatran 150 mg twice daily; †, rivaroxaban 20 mg once daily; ‡, apixaban 5 mg twice daily; §, edoxaban 60 mg once daily.
DOAC Trials Efficacy and Safety outcomes
![Page 6: Giancarlo Antonucci - Eventi5 · ICSH Laboratory Measurements of DOAC recommendations Trough drug level assessment for non emergent situations, with results reported in ng/mL International](https://reader031.vdocument.in/reader031/viewer/2022011918/6001c06be6acb16e56788dd8/html5/thumbnails/6.jpg)
![Page 7: Giancarlo Antonucci - Eventi5 · ICSH Laboratory Measurements of DOAC recommendations Trough drug level assessment for non emergent situations, with results reported in ng/mL International](https://reader031.vdocument.in/reader031/viewer/2022011918/6001c06be6acb16e56788dd8/html5/thumbnails/7.jpg)
Recommendations for Selecting an Anticoagulant Regimen
![Page 8: Giancarlo Antonucci - Eventi5 · ICSH Laboratory Measurements of DOAC recommendations Trough drug level assessment for non emergent situations, with results reported in ng/mL International](https://reader031.vdocument.in/reader031/viewer/2022011918/6001c06be6acb16e56788dd8/html5/thumbnails/8.jpg)
“Superiorità” dei DOACs
1. Farmacocinetica e farmacodinamica lineare
2. Finestra terapeutica più ampia
3. Non necessario monitoraggio
![Page 9: Giancarlo Antonucci - Eventi5 · ICSH Laboratory Measurements of DOAC recommendations Trough drug level assessment for non emergent situations, with results reported in ng/mL International](https://reader031.vdocument.in/reader031/viewer/2022011918/6001c06be6acb16e56788dd8/html5/thumbnails/9.jpg)
“Superiorità” dei DOACs
1. Farmacocinetica e farmacodinamica lineare
![Page 10: Giancarlo Antonucci - Eventi5 · ICSH Laboratory Measurements of DOAC recommendations Trough drug level assessment for non emergent situations, with results reported in ng/mL International](https://reader031.vdocument.in/reader031/viewer/2022011918/6001c06be6acb16e56788dd8/html5/thumbnails/10.jpg)
Frost et al. Br J Clin Pharmacol. 2013;76:776–86
Cinetica lineare
Peak
Trough
![Page 11: Giancarlo Antonucci - Eventi5 · ICSH Laboratory Measurements of DOAC recommendations Trough drug level assessment for non emergent situations, with results reported in ng/mL International](https://reader031.vdocument.in/reader031/viewer/2022011918/6001c06be6acb16e56788dd8/html5/thumbnails/11.jpg)
The effect of dabigatran plasma concentrations and patient characteristics on the frequency of
ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial.
Reilly PA et al. J Am Coll Cardiol2014;63:321-8.
-28%
![Page 12: Giancarlo Antonucci - Eventi5 · ICSH Laboratory Measurements of DOAC recommendations Trough drug level assessment for non emergent situations, with results reported in ng/mL International](https://reader031.vdocument.in/reader031/viewer/2022011918/6001c06be6acb16e56788dd8/html5/thumbnails/12.jpg)
Le differenze nella struttura chimica causano diversi effetti farmacocinetici e farmacodinamici
![Page 13: Giancarlo Antonucci - Eventi5 · ICSH Laboratory Measurements of DOAC recommendations Trough drug level assessment for non emergent situations, with results reported in ng/mL International](https://reader031.vdocument.in/reader031/viewer/2022011918/6001c06be6acb16e56788dd8/html5/thumbnails/13.jpg)
Le differenze nella struttura chimica causano diversi effetti farmacocinetici e farmacodinamici
Biodisponibilità ridotta PgP Attivazione epatica Eliminazione renale 80%
![Page 14: Giancarlo Antonucci - Eventi5 · ICSH Laboratory Measurements of DOAC recommendations Trough drug level assessment for non emergent situations, with results reported in ng/mL International](https://reader031.vdocument.in/reader031/viewer/2022011918/6001c06be6acb16e56788dd8/html5/thumbnails/14.jpg)
Le differenze nella struttura chimica causano diversi effetti farmacocinetici e farmacodinamici
Biodisponibilità PgP Attivazione epatica Eliminazione renale 80%
PgP CYTP450 (CYT3A4) Minor eliminazione renale
Assunzione con il cibo
![Page 15: Giancarlo Antonucci - Eventi5 · ICSH Laboratory Measurements of DOAC recommendations Trough drug level assessment for non emergent situations, with results reported in ng/mL International](https://reader031.vdocument.in/reader031/viewer/2022011918/6001c06be6acb16e56788dd8/html5/thumbnails/15.jpg)
Dose-Normalized Plasma Concentrations (ng/ml/mg) of Dabigatran According to Demographic Characteristics in the RE-LY Trial.
Reilly PA et al. J Am Coll Cardiol 2014;63:321-8.
![Page 16: Giancarlo Antonucci - Eventi5 · ICSH Laboratory Measurements of DOAC recommendations Trough drug level assessment for non emergent situations, with results reported in ng/mL International](https://reader031.vdocument.in/reader031/viewer/2022011918/6001c06be6acb16e56788dd8/html5/thumbnails/16.jpg)
Heidbuchel H et al. Europace. 2015 Oct;17(10):1467-507
Estimated drug half lives and effect on AUC NOAC plasma concentrationin different stages of CKD compared to healthy
controls
![Page 17: Giancarlo Antonucci - Eventi5 · ICSH Laboratory Measurements of DOAC recommendations Trough drug level assessment for non emergent situations, with results reported in ng/mL International](https://reader031.vdocument.in/reader031/viewer/2022011918/6001c06be6acb16e56788dd8/html5/thumbnails/17.jpg)
Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in
patients with atrial fibrillation treated for stroke prevention.
Mueck W. Mis-selwitz F. Clin Pharmacokinet 2011;50:675-86.
Plas
ma R
ivaro
xaba
n Con
centr
ation
(g/l)
![Page 18: Giancarlo Antonucci - Eventi5 · ICSH Laboratory Measurements of DOAC recommendations Trough drug level assessment for non emergent situations, with results reported in ng/mL International](https://reader031.vdocument.in/reader031/viewer/2022011918/6001c06be6acb16e56788dd8/html5/thumbnails/18.jpg)
Effect of Specific Populations on the Pharmacokinetics of Apixaban
* Dashed vertical lines illustrate pharmacokinetic changes that were used to inform dosing recommendations Apixaban Label 2018 US
![Page 19: Giancarlo Antonucci - Eventi5 · ICSH Laboratory Measurements of DOAC recommendations Trough drug level assessment for non emergent situations, with results reported in ng/mL International](https://reader031.vdocument.in/reader031/viewer/2022011918/6001c06be6acb16e56788dd8/html5/thumbnails/19.jpg)
Effect of Coadministered Drugs on the Pharmacokinetics of Apixaban
Apixaban Label 2019 US
![Page 20: Giancarlo Antonucci - Eventi5 · ICSH Laboratory Measurements of DOAC recommendations Trough drug level assessment for non emergent situations, with results reported in ng/mL International](https://reader031.vdocument.in/reader031/viewer/2022011918/6001c06be6acb16e56788dd8/html5/thumbnails/20.jpg)
Salazar DE et alThro b Haemost 2012;107:925-36
Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation.
![Page 21: Giancarlo Antonucci - Eventi5 · ICSH Laboratory Measurements of DOAC recommendations Trough drug level assessment for non emergent situations, with results reported in ng/mL International](https://reader031.vdocument.in/reader031/viewer/2022011918/6001c06be6acb16e56788dd8/html5/thumbnails/21.jpg)
“Superiorità” dei DOACs
1. Farmacocinetica e farmacodinamica lineare. Fattori condizionanti in maniera diversa per ogni farmaco:
– Età – Funzione renale – Peso – Farmaci – Varie combinazioni
![Page 22: Giancarlo Antonucci - Eventi5 · ICSH Laboratory Measurements of DOAC recommendations Trough drug level assessment for non emergent situations, with results reported in ng/mL International](https://reader031.vdocument.in/reader031/viewer/2022011918/6001c06be6acb16e56788dd8/html5/thumbnails/22.jpg)
“Superiorità” dei DOACs
1. Farmacocinetica e farmacodinamica lineare. 2. Finestra terapeutica più ampia. Ci sono soggetti possibilmente “fuori” dalla
finestra terapeutica? I trials registrativi
![Page 23: Giancarlo Antonucci - Eventi5 · ICSH Laboratory Measurements of DOAC recommendations Trough drug level assessment for non emergent situations, with results reported in ng/mL International](https://reader031.vdocument.in/reader031/viewer/2022011918/6001c06be6acb16e56788dd8/html5/thumbnails/23.jpg)
Challenges in comparing the non-vitamin K antagonist oral anticoagulants trials
![Page 24: Giancarlo Antonucci - Eventi5 · ICSH Laboratory Measurements of DOAC recommendations Trough drug level assessment for non emergent situations, with results reported in ng/mL International](https://reader031.vdocument.in/reader031/viewer/2022011918/6001c06be6acb16e56788dd8/html5/thumbnails/24.jpg)
A.Rubboli. G Ital Cardiol 2017;18(9 Suppl 2):3S-9S
Disegno degli studi registrativi con i nuovi anticoagulanti orali per la prevenzione di ictus e/o tromboembolia sistemica nella fibrillazione
atriale non valvolare
2008
X X
![Page 25: Giancarlo Antonucci - Eventi5 · ICSH Laboratory Measurements of DOAC recommendations Trough drug level assessment for non emergent situations, with results reported in ng/mL International](https://reader031.vdocument.in/reader031/viewer/2022011918/6001c06be6acb16e56788dd8/html5/thumbnails/25.jpg)
A.Rubboli. G Ital Cardiol 2017;18(9 Suppl 2):3S-9S
Disegno degli studi registrativi con i nuovi anticoagulanti orali per la prevenzione di ictus e/o tromboembolia sistemica nella fibrillazione
atriale non valvolare
Rimanere nella finestra terapeutica con sicurezza
X X
![Page 26: Giancarlo Antonucci - Eventi5 · ICSH Laboratory Measurements of DOAC recommendations Trough drug level assessment for non emergent situations, with results reported in ng/mL International](https://reader031.vdocument.in/reader031/viewer/2022011918/6001c06be6acb16e56788dd8/html5/thumbnails/26.jpg)
1.27% vs 1.6% ictus+embolismo 2.1% vs 3.1% sang.magg.
P <0,001
A.Rubboli. G Ital Cardiol 2017;18(9 Suppl 2):3S-9S
2008 2011 2015
![Page 27: Giancarlo Antonucci - Eventi5 · ICSH Laboratory Measurements of DOAC recommendations Trough drug level assessment for non emergent situations, with results reported in ng/mL International](https://reader031.vdocument.in/reader031/viewer/2022011918/6001c06be6acb16e56788dd8/html5/thumbnails/27.jpg)
Popolazione di pazienti trattata con dosi piene e ridotte dei NAO nei quattro mega-trial
![Page 28: Giancarlo Antonucci - Eventi5 · ICSH Laboratory Measurements of DOAC recommendations Trough drug level assessment for non emergent situations, with results reported in ng/mL International](https://reader031.vdocument.in/reader031/viewer/2022011918/6001c06be6acb16e56788dd8/html5/thumbnails/28.jpg)
Apixaban 5 mg twice daily and clinical outcomes in patients with atrial fibrillation and advanced age, low body weight, or high
creatinine: a secondary analysis of a randomized clinical trial.
Alexander JH et al. JAMA Cardiol.2016;1:673—81.
Rates of Major Bleeding
![Page 29: Giancarlo Antonucci - Eventi5 · ICSH Laboratory Measurements of DOAC recommendations Trough drug level assessment for non emergent situations, with results reported in ng/mL International](https://reader031.vdocument.in/reader031/viewer/2022011918/6001c06be6acb16e56788dd8/html5/thumbnails/29.jpg)
The effect of apixaban vs. warfarin on stroke or systemic embolism and major bleeding in patients ≥75 years in relation to apixaban dose.
![Page 30: Giancarlo Antonucci - Eventi5 · ICSH Laboratory Measurements of DOAC recommendations Trough drug level assessment for non emergent situations, with results reported in ng/mL International](https://reader031.vdocument.in/reader031/viewer/2022011918/6001c06be6acb16e56788dd8/html5/thumbnails/30.jpg)
Utilizzo di dosi piene e dosi ridotte dei quattro NAO (apixaban, dabigatran, edoxaban, rivaroxaban) nella vita reale in Italia negli
anni 2017 e 2018
![Page 31: Giancarlo Antonucci - Eventi5 · ICSH Laboratory Measurements of DOAC recommendations Trough drug level assessment for non emergent situations, with results reported in ng/mL International](https://reader031.vdocument.in/reader031/viewer/2022011918/6001c06be6acb16e56788dd8/html5/thumbnails/31.jpg)
The European Registry of Older Subjects With Atrial Fibrillation (EUROSAF)
INDICE PROGNOSTICO MULTIDIMENSIONALE (MPI)
![Page 32: Giancarlo Antonucci - Eventi5 · ICSH Laboratory Measurements of DOAC recommendations Trough drug level assessment for non emergent situations, with results reported in ng/mL International](https://reader031.vdocument.in/reader031/viewer/2022011918/6001c06be6acb16e56788dd8/html5/thumbnails/32.jpg)
Edoxaban versus warfarin in atrial fibrillation patients at risk of falling: ENGAGE AF-TIMI 48 analysis
Steffel J et al.. J Am Coll Cardiol 2016;68:1169-78.
Increased risk of falling: • major bleeding +30% • life-threatening bleeding +67% • all-cause death +45%
![Page 33: Giancarlo Antonucci - Eventi5 · ICSH Laboratory Measurements of DOAC recommendations Trough drug level assessment for non emergent situations, with results reported in ng/mL International](https://reader031.vdocument.in/reader031/viewer/2022011918/6001c06be6acb16e56788dd8/html5/thumbnails/33.jpg)
In the pivotal trials, NOACs were not tested in patients with a creatinine clearance < 30 mL/min.
European Heart Journal (2018) 00, 1–64
ESC guidelines do not recommend the introduction of NOACs in patients with a creatinine clearance < 30 mL/min
![Page 34: Giancarlo Antonucci - Eventi5 · ICSH Laboratory Measurements of DOAC recommendations Trough drug level assessment for non emergent situations, with results reported in ng/mL International](https://reader031.vdocument.in/reader031/viewer/2022011918/6001c06be6acb16e56788dd8/html5/thumbnails/34.jpg)
Stratified by age
Christina L. Fanola et al American Heart Journal 2017. 184:150-155
Incidence of severe renal dysfunction (CrCl<30 ml/min) among individuals taking warfarin and
implications for non-vitamin K oral anticoagulant
• Moderate baseline CKD • Coronary artery disease • Use of RAAS inhibitors, • Diuretics… • Inpatient admission • Heart failure • Diarrhea • Fever/Sepsis • Hyperglycemia • ……..
Risk Factors
![Page 35: Giancarlo Antonucci - Eventi5 · ICSH Laboratory Measurements of DOAC recommendations Trough drug level assessment for non emergent situations, with results reported in ng/mL International](https://reader031.vdocument.in/reader031/viewer/2022011918/6001c06be6acb16e56788dd8/html5/thumbnails/35.jpg)
*The median number of concomitant medications at baseline was 5 (25th, 75th percentiles, 4, 8).
Number of concomitant medications at baseline in the ROCKET AF study.
Piccini JP et al Circulation 2016;133:352-60.
![Page 36: Giancarlo Antonucci - Eventi5 · ICSH Laboratory Measurements of DOAC recommendations Trough drug level assessment for non emergent situations, with results reported in ng/mL International](https://reader031.vdocument.in/reader031/viewer/2022011918/6001c06be6acb16e56788dd8/html5/thumbnails/36.jpg)
Polypharmacy and the efficacy and safety of rivaroxaban versus warfarin in the prevention of stroke in patients with
nonvalvular atrial fibrillation.
Piccini JP et al Circulation 2016;133:352-60.
![Page 37: Giancarlo Antonucci - Eventi5 · ICSH Laboratory Measurements of DOAC recommendations Trough drug level assessment for non emergent situations, with results reported in ng/mL International](https://reader031.vdocument.in/reader031/viewer/2022011918/6001c06be6acb16e56788dd8/html5/thumbnails/37.jpg)
Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post-hoc analysis of the Aristotle trial.
Jaspers Focks J et al. BMJ 2016;353:i2868
0-5 drugs 6-8 drugs ≥9 drugs
0-5 drugs 6-8 drugs
≥9 drugs
Stroke or systemic embolism Major bleeding
![Page 38: Giancarlo Antonucci - Eventi5 · ICSH Laboratory Measurements of DOAC recommendations Trough drug level assessment for non emergent situations, with results reported in ng/mL International](https://reader031.vdocument.in/reader031/viewer/2022011918/6001c06be6acb16e56788dd8/html5/thumbnails/38.jpg)
Significant pharmacokinetic drug–drug interactions
Dabigatran
Edoxaban
Apixaban
Rivaroxaban
![Page 39: Giancarlo Antonucci - Eventi5 · ICSH Laboratory Measurements of DOAC recommendations Trough drug level assessment for non emergent situations, with results reported in ng/mL International](https://reader031.vdocument.in/reader031/viewer/2022011918/6001c06be6acb16e56788dd8/html5/thumbnails/39.jpg)
Dabigatran
Edoxaban
Apixaban
Rivaroxaban
Significant pharmacokinetic drug–drug interactions
![Page 40: Giancarlo Antonucci - Eventi5 · ICSH Laboratory Measurements of DOAC recommendations Trough drug level assessment for non emergent situations, with results reported in ng/mL International](https://reader031.vdocument.in/reader031/viewer/2022011918/6001c06be6acb16e56788dd8/html5/thumbnails/40.jpg)
I trials non hanno saggiato in maniera significativa l’interferenza dei farmaci
ESCLUSI
La strategia di evitare le associazioni con interazioni significative (inibitori e induttori forti) è tuttora l’unica proposta nelle LG
![Page 41: Giancarlo Antonucci - Eventi5 · ICSH Laboratory Measurements of DOAC recommendations Trough drug level assessment for non emergent situations, with results reported in ng/mL International](https://reader031.vdocument.in/reader031/viewer/2022011918/6001c06be6acb16e56788dd8/html5/thumbnails/41.jpg)
Y. Saito, Y. Kobayashi / Journal of Cardiology (2018)
after hospital
discharge?
History of guideline recommendations for triple therapy vs. dual therapy in patients with AF undergoing PCI.
WOEST No trials
INR 2-2,5
ISAR- TRIPLE PIONEER AF-PCI
RE-DUAL PCI trial
Peri-PCI
*DOAC with the lowest tested dose for stroke prevention Trial underpowered to assess efficacy outcomes (?)
*
![Page 42: Giancarlo Antonucci - Eventi5 · ICSH Laboratory Measurements of DOAC recommendations Trough drug level assessment for non emergent situations, with results reported in ng/mL International](https://reader031.vdocument.in/reader031/viewer/2022011918/6001c06be6acb16e56788dd8/html5/thumbnails/42.jpg)
Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation
Lopes RD, et al. N Engl J Med 2019;380:1509-24
The primary safety outcome, major or clinically relevant non major bleeding (ISTH)
![Page 43: Giancarlo Antonucci - Eventi5 · ICSH Laboratory Measurements of DOAC recommendations Trough drug level assessment for non emergent situations, with results reported in ng/mL International](https://reader031.vdocument.in/reader031/viewer/2022011918/6001c06be6acb16e56788dd8/html5/thumbnails/43.jpg)
Influence of antidepressants on hemostasis
Halperin and Reber Dialogues in Clinical Neuroscience - Vol 9 . No. 1 . 2007
Fluoxetine Paroxetine Sertraline
![Page 44: Giancarlo Antonucci - Eventi5 · ICSH Laboratory Measurements of DOAC recommendations Trough drug level assessment for non emergent situations, with results reported in ng/mL International](https://reader031.vdocument.in/reader031/viewer/2022011918/6001c06be6acb16e56788dd8/html5/thumbnails/44.jpg)
“Superiorità” dei DOACs
1. Farmacocinetica e farmacodinamica lineare. 2. Finestra terapeutica più ampia
– Indicate dosi ridotte – Attenzione dosi basse
![Page 45: Giancarlo Antonucci - Eventi5 · ICSH Laboratory Measurements of DOAC recommendations Trough drug level assessment for non emergent situations, with results reported in ng/mL International](https://reader031.vdocument.in/reader031/viewer/2022011918/6001c06be6acb16e56788dd8/html5/thumbnails/45.jpg)
“Superiorità” dei DOACs
1. Farmacocinetica e farmacodinamica lineare. 2. Finestra terapeutica più ampia 3. Non necessario monitoraggio. Forse però in alcuni casi.
![Page 46: Giancarlo Antonucci - Eventi5 · ICSH Laboratory Measurements of DOAC recommendations Trough drug level assessment for non emergent situations, with results reported in ng/mL International](https://reader031.vdocument.in/reader031/viewer/2022011918/6001c06be6acb16e56788dd8/html5/thumbnails/46.jpg)
Why laboratories do not perform DOAC testing?
• test availability, • rapid result turn-around-time (TAT), • difficulty in test performance and interpretation, • result variability, • lack of cutoff values, • poor definition of tests • lack of FDA approved methods for quantifying DOACs • a general reluctance to provide tests that may be
infrequently used
![Page 47: Giancarlo Antonucci - Eventi5 · ICSH Laboratory Measurements of DOAC recommendations Trough drug level assessment for non emergent situations, with results reported in ng/mL International](https://reader031.vdocument.in/reader031/viewer/2022011918/6001c06be6acb16e56788dd8/html5/thumbnails/47.jpg)
Laboratory drug measurements may be warranted in certain populations
Emergent situations
• bleeding • acute stroke • trauma • surgery
Dose adjustement
• the elderly • those at extremes of body
weight • those requiring drugs that
impact certain metabolic pathways
• those with renal impairment • poor responders
RC Gosselin. Int J Lab Hematol. 2019;41(Suppl. 1):33
![Page 48: Giancarlo Antonucci - Eventi5 · ICSH Laboratory Measurements of DOAC recommendations Trough drug level assessment for non emergent situations, with results reported in ng/mL International](https://reader031.vdocument.in/reader031/viewer/2022011918/6001c06be6acb16e56788dd8/html5/thumbnails/48.jpg)
ICSH Laboratory Measurements of DOAC recommendations
Trough drug level assessment for non emergent situations, with results reported in ng/mL
International Council for Standardization in Haematology (ICSH) 2018
![Page 49: Giancarlo Antonucci - Eventi5 · ICSH Laboratory Measurements of DOAC recommendations Trough drug level assessment for non emergent situations, with results reported in ng/mL International](https://reader031.vdocument.in/reader031/viewer/2022011918/6001c06be6acb16e56788dd8/html5/thumbnails/49.jpg)
Plasma levels and coagulation assays in patients treated with non-vitamin K antagonist oral anticoagulants
?
![Page 50: Giancarlo Antonucci - Eventi5 · ICSH Laboratory Measurements of DOAC recommendations Trough drug level assessment for non emergent situations, with results reported in ng/mL International](https://reader031.vdocument.in/reader031/viewer/2022011918/6001c06be6acb16e56788dd8/html5/thumbnails/50.jpg)
Direct Oral Anticoagulant Plasma Levels for the Management of Acute Ischemic Stroke
Institutional standard operating procedure for IVT in patients on DOACs with acute ischemic stroke
11.5% on VKAs and 9.2% on DOACs received thrombolysis
>500 pts
Armin Marsch et al.Cerebrovasc Dis 2019. DOI: 10.1159/000502335
![Page 51: Giancarlo Antonucci - Eventi5 · ICSH Laboratory Measurements of DOAC recommendations Trough drug level assessment for non emergent situations, with results reported in ng/mL International](https://reader031.vdocument.in/reader031/viewer/2022011918/6001c06be6acb16e56788dd8/html5/thumbnails/51.jpg)
Management strategies of the interaction between direct oral anticoagulant and drug-metabolizing enzyme inducers
A. Perlman et al. Journal of Thrombosis and Thrombolysis 2019 https://doi.org/10.1007/s11239-018-01804-7
95th 5th percentiles
……..were much less likely to have one of the medications stopped and more often had the DOACs’ dose increased
1596 hospitalized patients 1.4% concomitant EIDs.
![Page 52: Giancarlo Antonucci - Eventi5 · ICSH Laboratory Measurements of DOAC recommendations Trough drug level assessment for non emergent situations, with results reported in ng/mL International](https://reader031.vdocument.in/reader031/viewer/2022011918/6001c06be6acb16e56788dd8/html5/thumbnails/52.jpg)
?
S.Moll et al. Res Pract Thromb Haemost. 2019;3:152–155.
Extreme obesity would not be predicted to significantly affect PK and PD of apixaban and rivaroxaban; however, available clinical data is scarce. For dabigatran and edoxaban, clinical efficacy and clinical pharmacology data are even much less clear.
Morbidly obesity?
![Page 53: Giancarlo Antonucci - Eventi5 · ICSH Laboratory Measurements of DOAC recommendations Trough drug level assessment for non emergent situations, with results reported in ng/mL International](https://reader031.vdocument.in/reader031/viewer/2022011918/6001c06be6acb16e56788dd8/html5/thumbnails/53.jpg)
Morbid obesity?
• use warfarin • if a DOAC is chosen, to obtain a trough drug concentration
after five or more doses (when the DOAC has reached a steady-state concentration), to determine whether concentrations are roughly within the range published for other patient or healthy volunteer populations.
S.Moll et al. Res Pract Thromb Haemost. 2019;3:152–155.
![Page 54: Giancarlo Antonucci - Eventi5 · ICSH Laboratory Measurements of DOAC recommendations Trough drug level assessment for non emergent situations, with results reported in ng/mL International](https://reader031.vdocument.in/reader031/viewer/2022011918/6001c06be6acb16e56788dd8/html5/thumbnails/54.jpg)
“Superiorità” dei DOACs
1. Sono in aumento le prescrizioni in soggetti con un complesso profilo di rischio (nella maggior parte dei pazienti il rischio trombotico senza AC supera quello emorragico in corso di AC e i DOACs sono superiori al Warfarin)
2. E’ necessario migliorare la nostra confidenza con i farmaci nelle diverse situazioni per essere appropriati con i dosaggi ridotti
3. Il dosaggio al punto valle dell’anticoagulante allo steady state in alcune condizioni potrebbe in futuro rivelarsi utile